AMA is preparing to release new codes for COVID-19 vaccines in anticipation of their potential FDA approval.
As an example, they have posted codes for the Pfizer and Moderna vaccines.
- How will we ensure these new COVID codes make it into the OMOP Vocabulary? Does anyone know how the AMA deliberations manifest into the input data tables that we regularly download and integrate into our vocab?
- How should we coordinate across the OHDSI community to ensure we all align to the Vocabulary version when we begin to support vaccine surveillance efforts? (e.g. do we agree on 1 vocab version that we’ll all adopt at the same time? and then stay on a constant cadence (e.g. quarterly/semi-annually/annually) thereafter?)
- In the CDM, how do we model the exposure (e.g. the vaccine code) and the administration (e.g. the vaccine administration code for first or second dose)? Will we capture each vaccine code+administration code combos as distinct DRUG_EXPOSURE records? Presumably we will also capture NDC codes as DRUG_EXPOSURE records. This modeling decision will impact how we think about designing cohort definitions to extract ‘new vaccine users’ and distinguish first exposure from second exposure.
Given the public health impact and OHDSI’s potentially important role in supporting our regulators in their safety surveillance effort, I think this topic is worth OHDSI coming together to author clear data standards guidelines that we can embrace and apply across our community. I’m happy to work with others on this as more information comes to light.